Literature DB >> 31037414

Validation of the Turkish version of the International Consultation on Incontinence Questionnaire-vaginal symptoms (ICIQ-VS).

Işıl Köleli1, Bahar Sariibrahim Astepe2.   

Abstract

INTRODUCTION AND HYPOTHESIS: The International Consultation on Incontinence Questionnaire-Vaginal Symptoms (ICIQ-VS) was developed and validated in 2006 to evaluate vaginal symptoms, sexual matters, and quality of life of patients. This study aimed to validate the Turkish version of ICIQ-VS.
METHODS: The English version of the questionnaire was translated into Turkish. On the basis of the pelvic organ prolapse quantification (POP-Q) system, symptomatic women with ≥ 2 grade pelvic organ prolapse (POP) were included in the symptomatic (patient) group and asymptomatic women with ≤ 1 grade POP in the asymptomatic (control) group. The questionnaire was administered three times: after the first examination of the women (T1), 3 weeks after T1 (T2), and 3 months after the POP surgery (T3).
RESULTS: A total of 111 women were included in the study (symptomatic group, n = 53; asymptomatic group, n = 58). The missing data were ˂ 2%; the test-retest reliability was between 0.807 and 0.963, and the differences between the symptomatic and asymptomatic women were significant (p ˂ 0.001). A significant positive correlation existed between POP-Q and the vaginal symptom score, sexual matter score, and quality-of-life score (rs = 0.844, 0.393, and 0.698, respectively; p < 0.001). The Cronbach's alpha was 0.72 for the vaginal symptom score and 0.73 for the sexual matter score. The sensitivity to change was significant (p ˂ 0.05). The effect size values of the vaginal symptom score, sexual matter score, and quality-of-life score were 2.55, 2.33, and 1.56, respectively.
CONCLUSION: The Turkish version of ICIQ-VS was successfully validated in this study, and a newer version of the questionnaire was made available for assessing vaginal symptoms, sexual matters, and quality of life of patients with POP.

Entities:  

Keywords:  ICIQ-VS; Pelvic organ prolapse; Quality of life; Sexual matters; Turkish validation; Vaginal symptoms

Mesh:

Year:  2019        PMID: 31037414     DOI: 10.1007/s00192-019-03951-8

Source DB:  PubMed          Journal:  Int Urogynecol J        ISSN: 0937-3462            Impact factor:   2.894


  17 in total

1.  Validation, cultural adaptation and responsiveness of two pelvic-floor-specific quality-of-life questionnaires, PFDI-20 and PFIQ-7, in a Turkish population.

Authors:  Petek Balkanlı Kaplan; Necdet Sut; Hatice Kahyaoglu Sut
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2012-04-04       Impact factor: 2.435

Review 2.  Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines.

Authors:  F Guillemin; C Bombardier; D Beaton
Journal:  J Clin Epidemiol       Date:  1993-12       Impact factor: 6.437

3.  The validation of international consultation on incontinence questionnaires in the Greek language.

Authors:  Stavros Athanasiou; Athanasiou Stavros; Themistoklis Grigoriadis; Grigoriadis Themistoklis; Niki Kyriakidou; Kyriakidou Niki; George Giannoulis; Giannoulis George; Aristidis Antsaklis; Antsaklis Aristidis
Journal:  Neurourol Urodyn       Date:  2012-04-16       Impact factor: 2.696

4.  Prevalence and trends of symptomatic pelvic floor disorders in U.S. women.

Authors:  Jennifer M Wu; Camille P Vaughan; Patricia S Goode; David T Redden; Kathryn L Burgio; Holly E Richter; Alayne D Markland
Journal:  Obstet Gynecol       Date:  2014-01       Impact factor: 7.661

5.  Validation of the short form of the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) in a Turkish population.

Authors:  Cetin Cam; Pinar Sancak; Nazan Karahan; Ali Sancak; Cem Celik; Ates Karateke
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2009-07-01       Impact factor: 2.435

6.  Prevalence of symptomatic pelvic floor disorders in US women.

Authors:  Ingrid Nygaard; Matthew D Barber; Kathryn L Burgio; Kimberly Kenton; Susan Meikle; Joseph Schaffer; Cathie Spino; William E Whitehead; Jennifer Wu; Debra J Brody
Journal:  JAMA       Date:  2008-09-17       Impact factor: 56.272

7.  The Portuguese validation of the International Consultation on Incontinence Questionnaire-Vaginal Symptoms (ICIQ-VS) for Brazilian women with pelvic organ prolapse.

Authors:  José Tadeu Nunes Tamanini; Fernando G Almeida; Marcia Eli Girotti; Cássio L Z Riccetto; Paulo C R Palma; Luis Augusto S Rios
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-05-28

8.  Validation of the prolapse quality of life questionnaire (P-QOL) in a Turkish population.

Authors:  Cetin Cam; Mustafa Sakalli; Pinar Ay; Turhan Aran; Meltem Cam; Ates Karateke
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2007-08-10       Impact factor: 2.435

9.  Pelvic Organ Prolapse Quantification System (POP-Q) - a new era in pelvic prolapse staging.

Authors:  C Persu; C R Chapple; V Cauni; S Gutue; P Geavlete
Journal:  J Med Life       Date:  2011-02-25

Review 10.  Questionnaires to evaluate pelvic floor dysfunction in the postpartum period: a systematic review.

Authors:  Lea Tami Suzuki Zuchelo; Italla Maria Pinheiro Bezerra; Adna Thaysa Marcial Da Silva; Jéssica Menezes Gomes; José Maria Soares Júnior; Edmund Chada Baracat; Luiz Carlos de Abreu; Isabel Cristina Esposito Sorpreso
Journal:  Int J Womens Health       Date:  2018-08-08
View more
  2 in total

1.  Translation and validation of the international consultation on incontinence questionnaire-vaginal symptoms: the simplified Chinese version.

Authors:  Yufeng Liu; Yingyang Li; Tao Zhu; Tiantian Jia; Kexin Jiang; Enshe Jiang
Journal:  Int Urogynecol J       Date:  2022-08-24       Impact factor: 1.932

2.  Translation and linguistic validation of the Persian version of the International consultation on Incontinence Questionnaire Vaginal Symptoms.

Authors:  Abbas Ali Pourmomeny; Farnaz Foolad; Njmeh Sedighmehr; Mahtab Zargham; Farzaneh Sharifiaghdas
Journal:  J Res Med Sci       Date:  2021-08-30       Impact factor: 1.852

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.